Bridging the academic and industry interface to satisfy unmet clinical need

Lead Research Organisation: Cardiff University

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The MRC Proximity to Discovery scheme awards universities funds to help develop new collaborations, and ways of exchanging knowledge and skills.  The awards can be used to support activities that promote the value of academic-industry partnership, and enhance academic and industry researchers’ understanding of each other’s needs and capabilities.  This may be through people exchanges, creation of technology demonstrators, showcase events, commercialisation workshops and ‘entrepreneurs in residence’ schemes.  Such exchanges of knowledge and skills will boost the most fruitful collaborations between UK universities and life science companies.

Publications

10 25 50
 
Description ASTUTE 2020
Amount £40,000 (GBP)
Organisation European Commission 
Department Horizon 2020
Sector Public
Country European Union (EU)
Start 12/2017 
End 11/2018
 
Description Continuity Grant
Amount £23,000 (GBP)
Organisation Galecto Biotech 
Sector Private
Country Sweden
Start 03/2017 
End 10/2017
 
Description Industry Sponsored Studentship
Amount £110 (GBP)
Organisation Galecto Biotech 
Sector Private
Country Sweden
Start 10/2017 
End 09/2021
 
Description AML Biomarker collaboration 
Organisation Medical Research Council (MRC)
Country United Kingdom 
Sector Academic/University 
PI Contribution MRC Clinical Proteomics Centre for Stratified Medicine - SWATH MS is a new technology and its application of this to biomarker discovery is still in its infancy. This project has helped to develop new technical refinements and analytical approaches.
Collaborator Contribution The newly created Clinical Proteomics Centre for Stratified Medicine is a £12M investment by the MRC to create a world-leading facility for clinical proteomics. A key objective of the Centre is the pragmatic discovery of novel protein biomarkers to allow stratification of patients according to their disease endotype.
Impact Approximately 96 plasma samples from intermediate risk patients were separated into good and poor outcome groups and analysed by SWATH MS which uses mass spectrometry and a peptide library to identify differences in protein composition between the 2 groups. All samples were run in triplicate;81 of the samples passed QC. Initial models suggest reasonable accuracy (70 - 80%) of identifying good outcome patients using Random Forest machine learning
Start Year 2017
 
Description Collaborative Partnership 
Organisation Nexcelom Bioscience LLC
PI Contribution allowed us to conduct industrial-level screens of spheroids of cell lines (standards) and patient derived Mesenchymal Stem Cells.
Collaborator Contribution they brought their instrument to Cardiff for two weeks, with senior scientist. This new partner provided a screening imaging platform
Impact Publications in press
Start Year 2017
 
Description Reneuron 
Organisation Reneuron
Country United Kingdom 
Sector Private 
PI Contribution Exosome labelling optimisation and glioma model production
Collaborator Contribution bio-distribution of ReNeuron's exosomes; and also the investigation of radio-labelled exosomes and their use as PET imaging agents.
Impact in progress
Start Year 2017
 
Description Boston CYTO2017 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Boston CYTO2017
Year(s) Of Engagement Activity 2017
 
Description Infection Control Presentation 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Policymakers/politicians
Results and Impact Infection Control and Prevention Conference in Geneva in June 2017. Interest in the MRC P2D study was expressed by the World Health Organization
Year(s) Of Engagement Activity 2017